^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | ALK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical outcomes of ALK+ non-small cell lung cancer in Denmark
Published date:
10/10/2023
Excerpt:
A total of 209 ALK+ NSCLC patients were included….Patients with stage IIIb-IVb disease receiving an ALK-TKI as 1st line treatment had a median OS of 42.5 months with immature follow-up.
DOI:
10.1080/0284186X.2023.2263153
Source:
Title:
Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer
Published date:
09/01/2023
Excerpt:
Cases of advanced NSCLC patients with ALK positive confirmed by both Next Generation Sequencing (NGS) and immunohistochemistry were retrospectively collected….PFS of second-generation ALK inhibitors as first-line treatment was longer than that of Crizotinib as first-line (P<0.001).
DOI:
https://doi.org/10.1186/s12890-023-02618-x
Source:
Title:
Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors
Published date:
08/08/2023
Excerpt:
Patients with advanced ALK-positive NSCLC have prolonged survival after the introduction of ALK TKIs with a median OS that exceeds 5 years when ALK TKIs are used in the first-line setting.
Source:
Title:
Pathological response and tumor immune microenvironment remodeling of neoadjuvant ALK-TKIs in NSCLC with ALK.
Published date:
05/25/2023
Excerpt:
In this retrospective study, ALK+ NSCLC patients treated with neoadjuvant ALKi therapy... The objective response rate was 91.7% (11/12). All patients successfully underwent R0 resection. The major pathological response (MPR) rate was 75.0% (9/12), with 58.3% (7/12) achieving a pathological complete response (pCR)....Neoadjuvant ALKi therapy achieved an encouraging MPR rate of 75% and enhanced immune infiltration, suggesting its safety and feasibility for ALK+ resectable NSCLC.
DOI:
10.1200/JCO.2023.41.16_suppl.e20574
Source:
Title:
Clinical Profile, Practice pattern, and Outcomes with first-line therapy in ALK-positive Lung Cancer: Real-world data from resource constrained settings
Published date:
12/06/2022
Excerpt:
The median progression-free survival on first-line therapy for the entire cohort was 14.1 months (m) (95% CI: 12.2-15.9), with a significant difference between patients receiving ALK inhibitor in first line in any strategy vs. not in first line [17.2 m (95% CI:14.5-19.9) vs. 5.9 m (95% CI:4.2-7.6), p<0.001)....A majority of our ALK-positive NSCLC patients were exposed to ALK inhibitors through various support mechanisms. Those patients who could receive ALK inhibitors in the first-line had a significant survival advantage as compared to others.
DOI:
https://doi.org/10.1016/j.jtocrr.2022.100443
Source:
Title:
382P - Real-world data on treatment outcome of ALK positive non-small cell lung cancer from an Indian multi-centric cancer registry
Published date:
11/28/2022
Excerpt:
A total of 67 ALK-positive metastatic lung cancer patients were included...Use of ALKi in 1st line in ALK positive metastatic NSCLC patients resulted in improved PFS….Use of ALKi in any lines of therapy resulted in significantly prolonged OS.
Source:
Title:
Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non–small cell lung cancer
Published date:
05/13/2022
Excerpt:
There were 171 patients with ALK-positive advanced NSCLC admitted to our department from 2011 to 2019…The application of next-generation ALK-TKI after crizotinib failure significantly prolonged survival...
DOI:
https://doi.org/10.1111/1759-7714.14455